Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 20.0% in January

Lucid Diagnostics Inc. (NASDAQ:LUCD) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 3,797,518 shares, a decrease of 20.0% from the December 31st total of 4,747,257 shares. Based on an average daily volume of 519,285 shares, the short-interest ratio is currently 7.3 days. Approximately 3.0% of the shares of the company are sold short. Approximately 3.0% of the shares of the company are sold short. Based on an average daily volume of 519,285 shares, the short-interest ratio is currently 7.3 days.

Lucid Diagnostics Trading Up 4.4%

Shares of NASDAQ LUCD traded up $0.05 during midday trading on Friday, reaching $1.19. The company had a trading volume of 1,221,919 shares, compared to its average volume of 2,431,175. The business’s 50-day simple moving average is $1.13 and its 200 day simple moving average is $1.12. Lucid Diagnostics has a 1 year low of $0.89 and a 1 year high of $1.80. The stock has a market cap of $163.84 million, a P/E ratio of -1.14 and a beta of 1.22.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $1.35 million. Analysts predict that Lucid Diagnostics will post -0.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on LUCD. Needham & Company LLC restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research note on Thursday, November 13th. Ascendiant Capital Markets boosted their price target on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Wall Street Zen lowered Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lucid Diagnostics has an average rating of “Moderate Buy” and an average target price of $3.94.

Institutional Investors Weigh In On Lucid Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Lucid Diagnostics by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 4,523,997 shares of the company’s stock worth $4,569,000 after purchasing an additional 396,719 shares during the period. Masters Capital Management LLC boosted its holdings in Lucid Diagnostics by 46.6% during the third quarter. Masters Capital Management LLC now owns 3,999,273 shares of the company’s stock worth $4,039,000 after buying an additional 1,272,000 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Lucid Diagnostics by 38.3% in the 4th quarter. Aberdeen Group plc now owns 3,457,894 shares of the company’s stock worth $3,769,000 after acquiring an additional 957,894 shares during the period. Two Seas Capital LP acquired a new stake in Lucid Diagnostics in the third quarter valued at $3,030,000. Finally, Ghisallo Capital Management LLC purchased a new position in Lucid Diagnostics during the 3rd quarter valued at about $2,990,000. Institutional investors and hedge funds own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.